Molecular Biology Reports

, Volume 39, Issue 4, pp 4683–4690 | Cite as

Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk

  • Su-Qin Shen
  • De-Ke Jiang
  • Guo-Yuan Liu
  • Fang Chen
  • Long Yu
Article
First Online:
Received:
Accepted:

Abstract

Growing bodies of studies have been conducted on the association of TP53 Arg72Pro polymorphism with susceptibility to ovarian cancer and have yielded conflicting results. Thus, a meta-analysis was performed to summarize the possible association. 18 case–control studies, including 2,193 ovarian cancer cases and 5,175 controls were identified. The quality of the studies was assessed according to a predefined scale. The strength of the associations between TP53 Arg72Pro polymorphism and ovarian cancer was measured by crude odds ratios (ORs) with 95% confidence intervals (CIs). Overall, no significant association was found between TP53 Arg72Pro polymorphism and ovarian cancer risk when all studies pooled into the meta-analysis in all genetic model. In the subgroup analysis by ethnicity, still no association of this polymorphism with ovarian cancer risk was obtained for all comparison models. However, significantly decreased risks of ovarian cancer were found for Arg/Arg versus Arg/Pro+Pro/Pro (OR 0.84, 95% CI 0.74–0.96) when the analysis was restricted to high quality studies. Conversely, when it was restricted to low quality studies, significantly increased risks were observed for Arg/Arg versus Pro/Pro (OR 1.58, 95% CI 1.09–2.28) and Arg/Arg+Arg/Pro versus Pro/Pro: (OR 1.50, 95% CI 1.10–2.06), which might be spurious due to the poor design of these studies. In conclusion, this meta-analysis suggests that the Arg allele is at a moderately reduced risk for ovarian cancer and this polymorphism might protect against ovarian carcinogenesis.

Keywords

Ovarian cancer p53 Codon 72 Gene polymorphism Meta-analysis 

Abbreviations

Arg

Arginine

Pro

Proline

HWE

Hardy–Weinberg equilibrium

ORs

Odds ratios

CIs

Confidence intervals

This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by the National 973 Program of China (2004CB518605), the National 863 Project of China (2006AA020501), the National Key Sci-Tech Special Project of China (2008ZX10002-020), the Project of the Shanghai Municipal Science and Technology Commission (03dz14086), and the National Natural Science Foundation of China (30024001 and 30771188). This study was carried out in Shanghai, China.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  3. 3.
    Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L et al (2007) Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23:367–376PubMedGoogle Scholar
  4. 4.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 Mutations in human cancers. Science 253:49–53PubMedCrossRefGoogle Scholar
  5. 5.
    Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J et al (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961–963PubMedGoogle Scholar
  6. 6.
    Harris N, Brill E, Shohat O, Prokocimer M, Wolf D et al (1986) Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650–4656PubMedGoogle Scholar
  7. 7.
    Thomas M, Kalita A, Labrecque S, Pim D, Banks L et al (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092–1100PubMedGoogle Scholar
  8. 8.
    Qie M, Zhang Y, Wu J (2002) Study on the relationship between cervical cancer and p53 codon 72 polymorphism. Hua Xi Yi Ke Da Xue Xue Bao 33:274–275PubMedGoogle Scholar
  9. 9.
    Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M et al (2006) Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 100:173–178PubMedCrossRefGoogle Scholar
  10. 10.
    Li T, Lu ZM, Guo M, Wu QJ, Chen KN et al (2002) p53 Codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95:2571–2576PubMedCrossRefGoogle Scholar
  11. 11.
    Pegoraro RJ, Moodley M, Rom L, Chetty R, Moodley J (2003) P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int J Gynecol Cancer 13:444–449PubMedCrossRefGoogle Scholar
  12. 12.
    Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D et al (2004) P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 13:277–280PubMedCrossRefGoogle Scholar
  13. 13.
    Santos AM, Sousa H, Pinto D, Portela C, Pereira D et al (2006) Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 42:958–963PubMedCrossRefGoogle Scholar
  14. 14.
    Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F et al (2006) Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol 132:521–528PubMedCrossRefGoogle Scholar
  15. 15.
    Jiang DK, Wang WZ, Ren WH, Yao L, Peng B et al (2011) TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol 131:220–228PubMedCrossRefGoogle Scholar
  16. 16.
    Jiang DK, Ren WH, Yao L, Wang WZ, Peng B et al (2010) Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 76(3):765.e1-7PubMedCrossRefGoogle Scholar
  17. 17.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  18. 18.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  19. 19.
    Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar
  20. 20.
    Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629–634CrossRefGoogle Scholar
  21. 21.
    Malisic E, Jankovic R, Slavkovic D, Milovic-Kovacevic M, Radulovic S (2010) p53 Gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia. J BUON 15:101–106PubMedGoogle Scholar
  22. 22.
    Santos AM, Sousa H, Portela C, Pereira D, Pinto D et al (2006) TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 340:256–262PubMedCrossRefGoogle Scholar
  23. 23.
    Gadducci A, Cristofano CD, Zavaglia M, Giusti L, Menicagli M et al (2006) P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 26:687–693PubMedGoogle Scholar
  24. 24.
    Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM et al (2004) Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24:21–34PubMedCrossRefGoogle Scholar
  25. 25.
    Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG et al (2009) Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 69:2349–2357PubMedCrossRefGoogle Scholar
  26. 26.
    Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K et al (1997) The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4:239–245PubMedGoogle Scholar
  27. 27.
    Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V (1999) Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 6:193–197PubMedGoogle Scholar
  28. 28.
    Hogdall EV, Hogdall CK, Christensen L, Glud E, Blaakaer J et al (2002) Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 22:1859–1864PubMedGoogle Scholar
  29. 29.
    Kang S, Duan LH, Zhang JH, Guo W, Wang N et al (2004) Association of p53 gene polymorphism with susceptibility to ovarian cancer. Zhonghua Fu Chan Ke Za Zhi 39:754–758PubMedGoogle Scholar
  30. 30.
    Jiang DK, Yao L, Wang WZ, Peng B, Ren WH et al (2011) TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis. World J Gastroenterol 17:1227–1233PubMedCrossRefGoogle Scholar
  31. 31.
    Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2010) Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case–control studies. Int J Cancer 129:920–930PubMedCrossRefGoogle Scholar
  32. 32.
    Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365PubMedCrossRefGoogle Scholar
  33. 33.
    Chang CC, Hsieh YY, Tsai FJ, Tsai CH, Tsai HD et al (2002) The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril 77:43–45PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Su-Qin Shen
    • 1
  • De-Ke Jiang
    • 1
  • Guo-Yuan Liu
    • 1
  • Fang Chen
    • 1
  • Long Yu
    • 1
    • 2
  1. 1.State Key Laboratory of Genetic EngineeringFudan UniversityShanghaiChina
  2. 2.Institute of Biomedical ScienceFudan UniversityShanghaiChina

Personalised recommendations